Pediatric Pulmonary Institute and CF Center, Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel.
Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Pediatr Pulmonol. 2022 Oct;57(10):2335-2343. doi: 10.1002/ppul.26037. Epub 2022 Jun 15.
Cystic fibrosis (CF)-related diabetes (CFRD) affects 50% of CF adults. Gut microbial imbalance (dysbiosis) aggravates their inflammatory response and contributes to insulin resistance (IR). We hypothesized that probiotics may improve glucose tolerance by correcting dysbiosis.
A single-center prospective pilot study assessing the effect of Vivomixx® probiotic (450 billion/sachet) on clinical status, spirometry, lung clearance index (LCI), and quality of life (QOL) questionnaires; inflammatory parameters (urine and stool metabolomics, blood cytokines); and glucose metabolism (oral glucose tolerance test [OGTT]), continuous glucose monitoring [CGM], and homeostasis model assessment of IR (HOMA-IR) in CF patients.
Twenty-three CF patients (six CFRD), mean age 17.7 ± 8.2 years. After 4 months of probiotic administration, urinary cysteine (p = 0.018), lactulose (p = 0.028), arabinose (p = 0.036), mannitol (p = 0.041), and indole 3-lactate (p = 0.046) significantly increased, while 3-methylhistidine (p = 0.046) and N-acetyl glutamine (p = 0.047) decreased. Stool 2-Hydroxyisobutyrate (p = 0.022) and 3-methyl-2-oxovalerate (p = 0.034) decreased. Principal component analysis, based on urine metabolites, found significant partitions between subjects at the end of treatment compared to baseline (p = 0.004). After 2 months of probiotics, the digestive symptoms domain of Cystic Fibrosis Questionnaire-Revised improved (p = 0.007). In the nondiabetic patients, a slight decrease in HOMA-IR, from 2.28 to 1.86, was observed. There was no significant change in spirometry results, LCI, blood cytokines and CGM.
Changes in urine and stool metabolic profiles, following the administration of probiotics, may suggest a positive effect on glucose metabolism in CF. Larger long-term studies are needed to confirm our findings. Understanding the interplay between dysbiosis, inflammation, and glucose metabolism may help preventing CFRD.
囊性纤维化(CF)相关糖尿病(CFRD)影响 50%的 CF 成年人。肠道微生物失衡(失调)会加重其炎症反应,导致胰岛素抵抗(IR)。我们假设益生菌可能通过纠正失调来改善葡萄糖耐量。
一项单中心前瞻性试点研究,评估 Vivomixx®益生菌(4500 亿/袋)对 CF 患者的临床状况、肺活量测定、肺清除指数(LCI)和生活质量(QOL)问卷、炎症参数(尿液和粪便代谢组学、血液细胞因子)以及葡萄糖代谢(口服葡萄糖耐量试验[OGTT])、连续血糖监测[CGM]和胰岛素抵抗的稳态模型评估[HOMA-IR]的影响。
23 例 CF 患者(6 例 CFRD),平均年龄 17.7±8.2 岁。益生菌治疗 4 个月后,尿液中半胱氨酸(p=0.018)、乳果糖(p=0.028)、阿拉伯糖(p=0.036)、甘露醇(p=0.041)和吲哚 3-乳酸(p=0.046)显著增加,而 3-甲基组氨酸(p=0.046)和 N-乙酰谷氨酰胺(p=0.047)减少。粪便中 2-羟基异丁酸(p=0.022)和 3-甲基-2-氧代戊酸(p=0.034)减少。基于尿液代谢物的主成分分析发现,治疗结束时与基线相比,受试者之间存在显著的分区(p=0.004)。益生菌治疗 2 个月后,囊性纤维化问卷修订版的消化症状域得到改善(p=0.007)。在非糖尿病患者中,HOMA-IR 从 2.28 略微下降到 1.86。肺活量测定结果、LCI、血液细胞因子和 CGM 均无明显变化。
益生菌治疗后尿液和粪便代谢谱的变化可能提示对 CF 患者的葡萄糖代谢有积极影响。需要更大的长期研究来证实我们的发现。了解菌群失调、炎症和葡萄糖代谢之间的相互作用,可能有助于预防 CFRD。